Drug-coated balloons continue to show early promise


Preliminary data for the Lutonix Moxy drug-coated balloon were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 congress (21–25 September 2010), in Washington, USA.

The six-month results of the LEVANT I trial were presented by Dierk Scheinert, principal investigator, Heart Center Leipzig/Park Hospital, Leipzig, Germany, comparing drug-coated balloon catheter vs. angioplasty for femoropopliteal disease.


Scheinert told delegates that Moxy drug-coated balloon demonstrated a strong biologic effect on the inhibition of neointimal hyperplasia by achieving primary endpoint of improved late lumen loss. These data suggest that the Moxy drug-coated balloon is safe with a marked decrease in clinical events compared to angioplasty and shorter duration antiplatelet therapy appears feasible. Scheinert said a larger pivotal trial is warranted to further confirm the benefit of treating SFA and popliteal lesions with a drug-coated balloon.